文献速递肿瘤 PET/CT

根治性治疗后前列腺特异性抗原不可测时,18F-氟昔洛韦 PET/CT 是否仍有作用

Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
PubMed 文献 · Clin Nucl Med · 2020-01-01

本研究回顾性纳入 34 例根治性治疗后前列腺特异性抗原(PSA)不可测的前列腺癌患者,在 PSA 检查 2 周内行 18F-氟昔洛韦 PET/CT。结果 4 例(11.8%)阳性、30 例(88.2%)阴性;阳性者初诊 Gleason 评分均≥7 且为局部晚期(T3-T4)。作者认为该检查对初诊高 Gleason 评分、高疾病负荷、非典型组织学变异及有二线激素治疗和/或化疗史者获益最大。

要点

  • 34 例 PSA 不可测患者中 18F-氟昔洛韦 PET/CT 阳性 4 例(11.8%)、阴性 30 例(88.2%)。
  • 阳性者初诊 Gleason 评分均≥7 且为局部晚期(T3-T4)。
  • 阳性者非典型组织学变异 25% vs 阴性者 0%,极高危前列腺癌 50% vs 30%。

核心结论

  • 在根治性治疗后 PSA 不可测的前列腺癌患者中,18F-氟昔洛韦 PET/CT 对初诊 Gleason 评分≥7、高疾病负荷(T3-T4)、非典型组织学变异以及有二线激素治疗和/或化疗史者获益最大。

研究设计与样本

  • 本研究为回顾性研究,纳入 PSA 不可测且在接受 PSA 检查 2 周内行氟昔洛韦 PET/CT、期间无治疗或其他癌症的前列腺癌患者。
  • 共 34 例患者的 34 次氟昔洛韦 PET/CT 符合纳入标准,收集初诊时患者与肿瘤特征、治疗方案及 PET/CT 表现。
  • 采用描述性统计比较氟昔洛韦 PET/CT 阳性组与阴性组。

主要发现

  • 34 次氟昔洛韦 PET/CT 中阳性 4 次(11.8%)、阴性 30 次(88.2%)。
  • 阳性患者初诊 Gleason 评分均为 7 或更高且为局部晚期肿瘤(T3-T4)。
  • 阳性患者较阴性患者更常见的初诊特征为非典型组织学变异(25% vs 0%)和极高危前列腺癌(50% vs 30%)。
  • 阳性患者中 50% 接受二线激素治疗,阴性患者中 53.3% 接受一线激素治疗;未接受化疗者在阳性患者中占 75%、在阴性患者中占 96.7%。
  • 阳性氟昔洛韦 PET/CT 的受累部位为盆腔淋巴结(2/4,50%)、肺和纵隔淋巴结(1/4,25%)及前列腺切除床(1/4,25%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the role of F-fluciclovine PET/CT in the evaluation of prostate cancer (PC) patients after definitive treatment in the presence of undetectable prostate-specific antigen (PSA). PATIENTS AND METHODS: This retrospective study was conducted in PC patients who had undetectable PSA level and underwent fluciclovine PET/CT within a 2-week interval of PSA examination and without interval treatment or other cancer. Patient and tumor characteristics at initial diagnosis, treatment regimens, and findings on fluciclovine PET/CT were collected. Comparisons between groups of positive and negative fluciclovine PET/CT were done by using descriptive statistics. RESULTS: A total of 34 fluciclovine PET/CTs from 34 patients met the inclusion criteria. There were 4 positive (11.8%) and 30 negative fluciclovine PET/CTs (88.2%). All of the patients with positive results had an initial Gleason score of 7 or higher and locally advanced tumor (T3-T4). More common features at the time of diagnosis among positive study patients as compared with negative ones were atypical histologic variants (25% vs 0%) and very high-risk PC (50% vs 30%). Most of the patients with positive study received second-line hormonal therapy (HT) (50%), whereas patients with negative results received first-line HT (53.3%). Chemotherapy naivety was less common among positive patients (75% vs 96.7%). Sites of involvement on positive fluciclovine PET/CTs were pelvic lymph nodes (2/4, 50%), lung and mediastinal lymph node (1/4, 25%), and prostatectomy bed (1/4, 25%). CONCLUSIONS: In the presence of undetectable PSA in PC patients after definitive treatment, fluciclovine PET/CT would benefit most to patients with Gleason score of 7 or higher, high disease burden (T3-T4), and atypical histologic variants at the time of diagnosis, and the ones who have history of second-line HT and/or chemotherapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Teyateeti A, Teyateeti A, Macapinlac HA, et al. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment? Clin Nucl Med. 2020. PMID: 32604105. doi:10.1097/RLU.0000000000003122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。